January 13, 2022 05:27 PM ESTUpdated January 14, 08:02 AM
Deals

#JPM22 - Deal­mak­ing in 2022: What's Big Phar­ma look­ing for and what is it will­ing to pay?

John Carroll

Editor & Founder

John Car­roll:

Okay, well, thanks every­body for com­ing out to­day. We had a ton of reg­is­tra­tions for this pan­el dis­cus­sion about deal­mak­ing in 2022. I …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

A service from the Financial Times